STEMart announces the expansion of its genetic toxicology capabilities with the In Vivo Rat Micronucleus Test services.

Waters has announced the completion of its acquisition of BD’s Biosciences and Diagnostic Solutions businesses.

The growth of the genomics market is driven by the rising prevalence of genetic disorders and cancer, along with increasing awareness of early disease detection through genetic testing. WILMINGTON, ...

FAYETTEVILLE, GA, UNITED STATES, February 7, 2026 /EINPresswire.com/ -- Accurately isolating individual cells from ...

Q4 2025 Earnings Call February 9, 2026 8:30 AM ESTCompany ParticipantsCaspar Tudor - Head of Investor RelationsUdit Batra ...

A new study may change the way scientists think about the distance traveled by tiny bubbles carrying signals between cells ...

Turning to the acquired business contribution, following today's expected close of the transaction, we expect the Biosciences ...

Nicholas Richardson, DO, at Precision for Medicine, breaks down minimal residual disease and MRD negativity as FDA end points for faster myeloma approvals. Under this framework, MRD negativity is ...

An fresh look at trial results that propelled the only FDA approval of a chimeric antigen receptor (CAR) T-cell therapy for mantle cell lymphoma (MCL) shows prior treatment with ibrutinib, a ...

Waters Corporation (NYSE: WAT) ("Waters") today announced it has completed the previously announced combination with the ...

Diamond quantum nanoprobes detect immune cell inflammation by sensing electric charge shifts, opening a new path for real-time single-cell monitoring in immunology and cancer research.

Waters Corporation (NYSE:WAT) Q4 2025 Earnings Call Transcript February 9, 2026 Waters Corporation beats earnings ...